Melita has extensive experience in the diagnosis and management of genetic disorders and in supporting patients through complex genetic testing and decision-making.

She is also an expert in the growing field of interventional treatments for rare diseases, publishing widely in this field. She is the director of Myriad Trials Ltd (myriadtrials.com).

• Member of the British Society for Genomic Medicine and the Clinical Genetics Society
• Registered with the General Medical Council – revalidation March 2026
• Fellow of the Royal Society of Medicine
• International Skeletal Dysplasia Society
• Skeletal Dysplasia Group UK
• Skeletal Dysplasia Management Consortium
• Worshipful Society of Apothecaries

• Rare genetic disorders
• Chromosomal disorders
• Developmental delay
• Prenatal and reproductive genetics
• Genetic counselling for families
• Interpretation of genetic testing
• Neuropredictive testing
• Growth disorders
• Clinical trials
• Achondroplasia
• Hypochondroplasia
• Skeletal dysplasia

Melita trained in clinical genetics at leading London centres, including Guy’s and St Thomas’ NHS Trust, where she has her NHS base. She has worked extensively within the NHS and academic settings, King’s College London, from where she received her MD(Res) degree in 2014.

Melita practises widely in rare disease genetics and has a particular expertise in skeletal dysplasia conditions, such as achondroplasia and hypochondroplasia, and genetic disorders of growth.

Melita is committed to providing clear, thoughtful, and patient-centred consultations, ensuring that individuals and families understand their genetic information and available options.

Dr Rhoda Akilapa is a Consultant in Clinical Genetics at Guy’s and St Thomas’ NHS Foundation Trust.

She specialises in rare diseases, with particular expertise in skeletal dysplasia and connective tissue disorders.

• Member of the Royal College of Paediatrics and Child Health (MRCPCH)
• Member of the British Society for Genomic Medicine (BSGM)
• Member of the Clinical Genetics Society (CGS)
• Committee Member, Skeletal Dysplasia Group (UK)
• Expert Panel Member, ClinGen Gene Curation Expert Panel (GCEP)
• Member of the International Skeletal Dysplasia Society
• Trustee of the Cilliopathy Alliance

• Rare genetic disorders (children and adults)
• Skeletal dysplasia and disorders of growth
• Connective tissue disorders (including Ehlers–Danlos spectrum)
• Cardiac genetics and inherited cardiovascular conditions
• Prenatal and reproductive genetics
• Chromosomal and neurodevelopmental conditions
• Genetic counselling
• Interpretation of complex genomic testing, including whole genome sequencing
• Clinical trials and emerging therapies in rare disease

Dr Akilapa trained in Clinical Genetics in London and is a Consultant at Guy’s and St Thomas’ NHS Foundation Trust.

She leads specialist clinics across a range of genetic services and contributes to multidisciplinary care alongside experts in endocrinology, cardiology, orthopaedics, neurology, and obstetrics.

In addition to her clinical work, she is actively involved in clinical research, including industry-sponsored and investigator-led trials, with a focus on improving diagnosis and expanding treatment options for rare genetic conditions.

Dr Elizabeth Forsythe is a Consultant Clinical Geneticist at Genetics London Ltd, specialising in the diagnosis and care of children and adults with rare genetic conditions. She has many years of experience working in the NHS and leading research to develop new treatments for rare diseases, including Bardet-Biedl syndrome and genetic forms of obesity.

What she does

• Helps families understand the cause of health and developmental problems through genetic testing and clear, supportive explanations.
• Looks after people with rare conditions and has a specialist interest in genetic obesity syndromes, Bardet-Biedl syndrome and ciliopathy disorders.
• Works on new treatments for rare diseases, including gene therapy.
• Runs and supports clinical trials and patient registries so that care and future treatments can continue to improve.

• Member of the Royal College of Paediatrics and Child Health (MRCPCH)
• British Society for Genomic Medicine, Clinical Genetics Society
• Registered with the General Medical Council
• Board member, Bardet-Biedl Syndrome UK Scientific Advisory Group
• Board member, Ciliopathy Alliance UK

• Helps families understand the cause of health and developmental problems through genetic testing and clear, supportive explanations.
• Looks after people with rare conditions and has a specialist interest in genetic obesity syndromes, Bardet-Biedl syndrome and ciliopathy disorders.
• Works on new treatments for rare diseases, including gene therapy.
• Runs and supports clinical trials and patient registries so that care and future treatments can continue to improve.

Dr Forsythe studied medicine in London and completed specialist training in clinical genetics at Great Ormond Street Hospital. She completed her PhD at University College London, focusing on developing innovative therapies for rare diseases. She co-leads national clinics for Bardet-Biedl syndrome, and set up the first UK treatment clinic using a new medication (setmelanotide). Dr Forsythe is also involved in an international gene therapy programme for Bardet-Biedl syndrome. Dr Forsythe is committed to improving outcomes for people living with rare diseases through driving policy and advising in parliamentary round table discussions.

She is widely published in the field of rare diseases and is regularly invited to speak at national and international meetings. Dr Forsythe works closely with patient organisations and strongly believes in partnership with families, making sure that care is compassionate, understandable, and tailored to each person’s needs.

Dr Bowdin has an extensive background in pioneering genomic technology. She was one of the first Clinical Geneticists in the world to have access to whole-genome sequencing technology for use in clinical care and co-developed the SickKids Genome Clinic for children with undiagnosed conditions. She brings a wealth of international experience to her practice, having spent nine years in Canada developing specialised genetics services.

• Membership of the Royal College of Paediatrics and Child Health
• Member of the British Society of Genomic Medicine
• Secretary of the Clinical Genetics Society
• Speciality Lead for Clinical Genetics at Addenbrooke’s Hospital, Cambridge
• Former Medical Director of the East Genomics Laboratory Hub (2019-2026)

• Paediatric genetics and cardiovascular genetics, including connective tissue disorders
• Cardiac genetics
• Prenatal and paediatric genetics
• Craniofacial genetics, including cleft lip and palate and craniosynostosis
• Fetal (prenatal) medicine
• Preimplantation Genetic Diagnosis
• Whole genome sequencing technology for clinical care

After initially training in paediatrics, Dr Bowdin trained in Clinical Genetics in Oxford and Birmingham. During her genetics training, she undertook a Master’s degree in Prenatal Genetics, Preimplantation Genetic Diagnosis, and Fetal Medicine at University College London.

Having completed two years as a Consultant Clinical Geneticist in the UK, she moved to the Hospital for Sick Children in Toronto, Canada, where she worked for nine years. There, she developed the paediatric cardiac genetics service and was responsible for the craniofacial and cleft lip and palate genetics clinics.

Upon returning to a consultant position in Cambridge, UK, she took on major leadership roles within the region. Dr Bowdin served as the Medical Director of the East Genomics Laboratory Hub in Cambridge from 2019 to 2026 and is currently the Speciality Lead for Clinical Genetics at Addenbrooke’s Hospital, Cambridge.

Cancer is understandably a worry for many of us. Sadly, it may already have touched your own life, or the life of someone you love. When cancer affects an individual or a family, it can bring with it difficult questions and uncertainty.

The vast majority of cancers are not caused by a single inherited genetic change. However, in a small but important proportion of families, inherited genetic factors can significantly increase the risk of developing certain cancers.

My role is to help individuals with a personal or family history of cancer make sense of this complex area. I assess when there may be evidence of an inherited cancer predisposition and, where appropriate, discuss whether genetic testing could provide valuable information about cancer risk — both for the individual and potentially for their wider family.

For those found to be at increased risk, I can provide personalised advice about cancer surveillance and screening, and guide you towards evidence-based approaches to reducing risk, which may include risk-reducing medication or surgery.

I can help you navigate answers to important questions such as:

· What is my risk of developing a particular type of cancer?

· Is there anything I can do to reduce my risk of developing a particular cancer?

· Could other members of my family also be at increased risk?

· If I have an inherited cancer predisposition, does this mean I will definitely develop cancer?

My aim is not simply to identify genetic risk, but to turn that knowledge into meaningful action -helping you and your family understand your risks, make informed decisions, and importantly take proactive steps towards protecting your future health. I am passionate about providing high-quality, evidence-based advice, and compassionate, patient-centred care.

• Personalised Cancer Risk Assessment
  • I can provide an individualised assessment of your cancer risk based on your personal and family history, taking into account patterns of cancer within the family, the types of cancer diagnosed, ages at diagnosis, and other relevant risk factors. Where appropriate, I can help determine whether your history suggests an increased likelihood of an inherited cancer predisposition and what this may mean for you and your family.
• Cancer screening advice
  • For individuals assessed to be at increased risk of cancer, I provide personalised advice about appropriate surveillance. This may include recommending earlier or more frequent screening, or discussing specialist surveillance programmes. My aim is to ensure that screening is tailored to your individual level of risk and based on current evidence and guidelines.
• Genetic Testing for inherited cancer risk
  • I can help you understand whether genetic testing may be appropriate, explain what testing can and cannot tell you, and support you through the decision-making process around genetic testing. This may include:
  • Diagnostic genetic testing: testing one or more genes known to be associated with an increased predisposition to cancer. This may be because you have had a cancer diagnosis, or because you have a strong family history of cancer.
  • Predictive genetic testing: testing for a specific genetic variant that has already been identified in a family, to determine whether an individual has inherited the same variant and may therefore have an increased risk of developing certain cancers.
• Understanding complex genetic test results
  • Genetic test reports can be complex and difficult to interpret. I can help you understand what your results mean in the context of your personal and family history. A genetic test result does not always provide a simple “yes” or “no” answer. I can help explain what your result means for your future cancer risk, what it may mean for other members of your family, and whether any further assessment or testing may be appropriate.
• Support and counselling around genetic results
  • Receiving genetic results can raise important and sometimes difficult questions. I provide clear, compassionate support to help you understand your results and consider what they mean for you and your family.
  • This may include discussing cancer risk, screening and risk-reducing options, implications for relatives, and the emotional or practical impact of genetic information. My approach is to provide information in a way that enables you to make informed decisions that are right for you.
• Supporting individuals and families with inherited cancer syndromes
  • I provide ongoing support to individuals and families affected by inherited cancer predisposition syndromes. This may include helping you understand your inherited condition, discussing your individual cancer risks, advising on appropriate evidence-based surveillance and risk-reduction strategies, and considering the implications for other family members.
  • My approach is personalised, evidence-based and family-focused. Genetic information can sometimes feel overwhelming, but with the right support it can provide valuable knowledge — helping you understand your risks, make informed choices, and take proactive steps to protect your health and the health of those you love.

Sabrina was awarded multiple prestigious academic awards during her medical training at the University of St Andrews and the University of Cambridge.

Sabrina completed postgraduate training in adult clinical medicine, obtaining Membership of the Royal College of Physicians (MRCP) in 2012, before undertaking specialist training in Clinical Genetics at two leading NHS genetics services in London. Sabrina also completed a three-year Clinical Research Fellowship at the Institute of Cancer Research and The Royal Marsden Hospital. This experience provided in-depth expertise in cancer genetics and genomics, while developing her understanding of the research underpinning modern approaches to inherited cancer risk and personalised patient care. In 2016, Sabrina completed a Postgraduate Certificate in the Interpretation and Clinical Application of Genomic Data at St George’s, University of London, further strengthening her expertise in the rapidly evolving field of genomic medicine.

Sabrina has been practising as a Consultant in Clinical Genetics since 2019, with a specialist clinical focus on Cancer Genetics. Her career brings together extensive clinical experience and genomic expertise to provide highly specialist, evidence-based care to individuals and families affected by inherited cancer risk.